Background Hepatitis D virus (also known as hepatitis delta virus) can establish a persistent infection in people with chronic hepatitis B, leading to accelerated progression of liver disease. In sub-Saharan Africa, where HBsAg prevalence is higher than 8%, hepatitis D virus might represent an important additive cause of chronic liver disease. We aimed to establish the prevalence of hepatitis D virus among HBsAg-positive populations in sub-Saharan Africa.
Introduction
Liver cirrhosis and hepatocellular carcinoma accounted for more than 3% of adult deaths in sub-Saharan Africa in 2013, and this proportion is rising.
1 Chronic infection with hepatitis B virus, which has an estimated population prevalence of 8·8%, is the main cause. 2 Hepatitis D virus (also known as hepatitis delta virus) is a small satellite sub-virus that requires the presence of HBsAg to propagate. 3 Hepatitis B and D virus infections can occur simultaneously, which frequently results in clearance of both viruses, or as superinfection in chronic hepatitis B virus carriers, which often leads to persistence of hepatitis D virus. 4 Individuals concomitantly infected with hepatitis B and D viruses can mount transient serological responses before clear ance; thus, screening for hepatitis-D-virus-specific antibody reliably identifies cases of chronic superinfection but is less accurate for ascertainment of overall rates of exposure. 4 Chronic hepatitis B and D virus co-infection is associated with expedited progression to cirrhosis, and has been characterised as the most severe form of viral hepatitis. 5 In sub-Saharan Africa, where 4·8% of adults are living with HIV, hepatitis B virus infection and HIV often coexist, albeit with geographical variations. 6, 7 Coinfection with HIV, hepatitis B virus, and hepatitis D virus could be an important specific cause of liver-related morbidity and mortality. 8, 9 The only treatment for hepatitis D virus is pegylated interferon-α, and less than 30% attain sustained virological responses. Novel drug classes, including prenylation and entry inhibitors, are in development. 4, 10, 11 Despite widely held assumptions of hyper-endemicity, no previous systematic analyses have been done of the epidemiology of hepatitis D virus in sub-Saharan Africa. Routine testing for hepatitis D virus is rare in clinical practice, and because of low rates of case ascertainment, the overall contribution of the virus to the burden of liver disease in the region is unknown. 5 We aimed to define the available evidence on the prevalence of hepatitis D virus in sub-Saharan Africa and identify research needs.
Methods

Search strategy and selection criteria
We did a systematic review and meta-analysis of studies of the prevalence of hepatitis D virus in sub-Saharan Africa, including added data for anti-hepatitis D virus and hepatitis D virus RNA prevalence from two HIVpositive cohorts in Ghana and Malawi, where scarce data were previously available. AJS searched PubMed, Embase, and Scopus for studies published in any language between Jan 1, 1995, and Aug 30, 2016 , in which the prevalence of anti-hepatitis D virus antibody or hepatitis D virus RNA was reported. Search strings included sub-Saharan Africa, the countries therein, and perm utations of hepatitis D virus (appendix). MC and AJS independently assessed articles for inclusion; disagree ments were resolved by consensus. Hepatitis D virus seroprevalence was defined as reported detection of anti-hepatitis D virus by enzyme immunoassay in HBsAg-positive patients. To be included in our review, hepatitis D virus seroprevalence, patient selection methods, and the geographical and clinical setting had to be reported in the study. 12 Data for infants or children whose age was not described were excluded to avoid confounding from potential maternal antibody transfer. Populations undergoing assessment in liver disease clinics and those sampled from other populations (defined as general populations) were analysed separately. We contacted study authors for clarification as required. Genotypic data were compiled from studies in which hepatitis D virus RNA was sequenced. We also searched the public sequence databases European Nucleotide Archive and GenBank with the same search strategy used in our initial search (appendix). We excluded genotypic data from studies of immigrants from subSaharan Africa who now reside outside the region. Our study was done in accordance with PRISMA recommendations.
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Statistical analysis
AJS extracted seroprevalence data. Duplicate data from the same locations were excluded. Confidence intervals (CIs) were computed by the Wilson method and pooled seroprevalence was calculated with the DerSimonianLaird random-effects model with Freeman-Tukey double arcsine transformation. 14, 15 We chose a random-effects model a priori because we anticipated heterogeneity arising from variation in study geography and populations. To avoid small sample bias in the randomeffects model, we excluded studies in which fewer than ten patients underwent RNA testing, for our calculation of the pooled estimate of hepatitis D virus RNA positivity in patients seropositive for hepatitis D virus. Betweenstudy heterogeneity was assessed with the I² statistic. Seroprevalence in patients with liver disease compared
Research in context
Evidence before this study We searched PubMed, Embase, and Scopus with the terms "hepatitis delta" and "sub-Saharan Africa" and the countries therein for studies published in any language between Jan 1, 1995, and Aug 30, 2016 (appendix). We identified no systematic reviews of hepatitis D virus seroprevalence in the region. In narrative reviews, cited studies predominantly done in west Africa suggested a seroprevalence of between 12% and 67% from diverse populations in Gabon, Cameroon, and Nigeria. We identified no studies in which risk factors for hepatitis D virus infection or a possible association between hepatitis D virus infection and HIV status were analysed.
Added value of this study
In our analysis, we systematically compiled available data for hepatitis D virus epidemiology in sub-Saharan Africa, added novel cohort data from Malawi and Ghana, and provided pooled estimates of seroprevalence by region and population group. Our findings suggest substantial geographical variability, with pockets of hyperendemicity in central Africa and low seroprevalence in southern Africa. Overall, hepatitis D virus seroprevalence among HBsAg-positive populations in west and central Africa exceeds the estimated global seroprevalence.
Published data do not allow firm conclusions to be drawn about risk factors for hepatitis D virus infection, including any possible association with HIV status. In most studies, detection of anti-hepatitis D virus was not confirmed with a second assay, and hepatitis D virus RNA detection was reported in only a few studies.
Implications of all the available evidence
Hepatitis D virus infection makes a potentially important contribution to the burden of liver disease in sub-Saharan Africa, particularly in west and central Africa, but important gaps in knowledge remain and more research is needed. Epidemiological data for east and southern Africa are insufficient. The natural history of infection with genotypes 5-8, which are endemic to Africa, remains to be characterised, including ascertainment of prevalence among patients with well characterised liver disease. Methods of detection of hepatitis D virus RNA need to be standardised, and the reliability of hepatitis D virus antibody and RNA testing in African settings should be investigated. Studies are needed to identify specific risk factors for hepatitis D virus infection, and guide the formulation of prevention and management policies.
See Online for appendix with that in those without liver disease were pooled with a DerSimonian-Laird random-effects model. 14 Metaregression was done with a residual maximum-likelihood model to examine for sources of heterogeneity related to study location, rural versus urban setting, and the effect of HIV infection by comparison with data from cohorts in which the HIV status of recruited participants was known. We did sensitivity analyses to investigate the effect of population source and of using potentially unrepresentative samples. Risk of bias was independently assessed by AJS and MC with a prevalence critical appraisal tool. 16 Publication bias was assessed by inspection of a funnel plot and Egger's test. 17 Analyses were done with metan, metaprop, and metareg packages in Stata (version 14.2).
Role of the funding source
The study funder had no role in study design; data collection, analysis, or interpretation; or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
Our search returned 374 records, 30 of which met the inclusion criteria (figure 1). The 30 studies described 40 populations from 15 countries: 23 cohorts from eight west African countries (Benin, Burkina Faso, The Gambia, Ghana, Guinea-Bissau, Mauritania, Nigeria, and Senegal), [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] ten cohorts from three central African countries (Cameroon, Central African Republic, and Gabon), 18, [35] [36] [37] [38] [39] [40] [41] [42] [43] and seven cohorts from four east or southern African countries (Botswana, Mozambique, South Africa, and Tanzania; figure 2; table) . 19, [44] [45] [46] We added data from previously characterised cohorts coinfected with HIV and hepatitis B virus infection in Malawi and Ghana (appendix). 48, 49 Eight studies included populations 21, 33, 34, 36, 37, 40, 43, 46 from rural settings; the rest were done in urban or mixed populations. Seven commercial enzyme immunoassays were used in studies to test for total anti-hepatitis D virus; in four studies 28, 35, 36, 42 the test manufacturer was not stated (appendix). Patients were recruited in various settings: through community surveys, 33, 34, 40 via blood donation, 25, 30, 31, 34, 45 in antenatal care, 19, 21, 37, 39, 44 during testing of health-care workers, 36 at HIV clinics, 18, 22, 23, 41, 44, 46 and at general medical clinics (patients did not have known liver disease). 25, 32 Eight cohorts comprised exclusively HIV-positive participants. 18, 22, 23, 41, 44, 46 HIV testing was done in 13 other cohorts: people with HIV were excluded from seven cohorts, 24, 25, 30, 36, 43, 44 whereas the remaining six cohorts 19, 21, 31, 34, 37, 45 had a HIV prevalence of 0·6-13·8%. HIV status was not reported in 19 cohorts. 18, 20, 24, [26] [27] [28] [29] [32] [33] [34] [35] [38] [39] [40] 42, 47 In one study, 31 HIV prevalence was compared according to hepatitis D virus serostatus, but it lacked statistical power because only six participants seropositive for hepatitis D virus were included.
Among general populations with HBsAg, hepatitis D virus seroprevalence varied widely within geographical regions, from 0·34% to 27·27% in adults in west Africa, 18, 21, 25, 26, [30] [31] [32] 7·34% to 66·13% in central Africa, 36, 37, 39, 40, 43 and 0·00% to 5·02% in east and southern Africa 19, [44] [45] [46] (figure 3A; table) . One cluster-sampling survey 40 done in a rural area in northern Gabon was an extreme outlier, with a seroprevalence of 66·13%. Pooled overall seroprevalence of hepatitis D virus was 8·39% (95% CI 4·73-12·85; figure 3A ). Seroprevalence was 7·33% in west Africa (95% CI 3·55-12·20), 25·64% in central Africa (95% CI 12·09-42·00), and 0·05% (95% CI 0·00-1·78%) in east and southern Africa; study region was significantly associated with seroprevalence (p=0·01). According to meta-regression analysis, relative to the reference category of west Africa, seroprevalence was significantly higher in central Africa (coefficient 0·17 [95% CI 0·04-0·30]; p=0·012), but was not significantly different in east or southern Africa (coefficient -0·07 [95% CI -0·21 to 0·07]; p=0·31). The seroprevalence of hepatitis D virus was significantly higher in studies in rural areas than in those in urban areas, but not after adjustment for confounding by African region (coefficient for rural dwelling 0·10 [95% CI -0·03 to 0·24]; p=0·13). Among the 21 studies in which HIV status was reported, seroprevalence of hepatitis D Among HBsAg-positive patients recruited from hepatology clinics, seroprevalence ranged from 0·00% to 33·11% among nine cohorts in Ghana, Mauritania, Nigeria, and Senegal, 18, 20, 24, [27] [28] [29] [30] 47 with a pooled estimated seroprevalence of 9·57% (95% CI 2·31-20·43) in west Africa (figure 3B). In central Africa, the pooled prevalence from three studies 18, 35, 38 from Cameroon and Central African Republic was 37·77% (95% CI 12·13-67·54). We noted significant heterogeneity between west and central Africa (p=0·04; figure 3B ; table). In the five studies 24, 27, 29, 30, 47 from Mauritania, Nigeria, and Senegal in which patients with evidence of liver disease (severe fibrosis, cirrhosis, or hepatocellular carcinoma) were directly compared with asymptomatic controls without evidence of liver disease drawn from the same population, the pooled odds ratio of the presence of anti-hepatitis D virus among HBsAg-positive patients with liver disease was 5·24 (95% CI 2·74-10·01; p<0·0001; figure 4).
Testing for hepatitis D virus RNA by qualitative PCR in patients seropositive for hepatitis D virus was done in 324 patients (174 from general populations and 150 from liver-disease populations) in 16 populations. 18, [22] [23] [24] [25] [26] 41, 44, 46 RNA positivity ranged from 0% to 69% in general populations, and from 0% to 71% in liver-disease populations (table), but some studies had very small patient numbers. Three studies 25, 26 in blood donors, pregnant women, and medical inpatients from a site in Mauritania were included, in which the prevalence of RNA detected ranged from 62% to 69%, with a pooled estimate of 64% (95% CI 56-73). In a study 46 done in Tanzania, no hepatitis D virus RNA was detected in 11 participants with HIV who were positive for antihepatitis D virus. In two studies in patients with liver disease from Mauritania and Central African Republic, RNA detection rates were 62% and 61% respectively, with a pooled estimate of 62% (95% CI 54-70). Hepatitis D virus genotype data were included in seven stud ies. figure 5 ; appendix).
In our quality assessment, we identified recurrent issues with respect to incomplete description of study populations and sampling methods (figure 6). Testing methods did not commonly include confirmation of anti-hepatitis D virus seropositivity by either retesting or hepatitis D virus RNA detection. In most studies, hepatitis D virus epidemiology was not a primary outcome (data not shown), and none of the studies included sample size calculations or estimates of the completeness of the data, including the proportion of eligible people who participated in the study. In several studies, populations were selected that might have not been representative of the general population, including blood donors, health-care workers, and medical outpatients (figure 6). In a sensitivity analysis, exclusion of these studies did not affect estimates of overall prevalence of hepatitis D virus infection (p=0·92). Furthermore, in studies done in the general population, the type of patient recruited or location of recruitment (eg, blood donors, perinatal care, community, health-care workers, medical outpatients, HIV clinics) was not significantly associated with hepatitis D virus seroprevalence (p=0·30). No evidence of publication bias was evident in the funnel plot (appendix) or by the Egger's test (p=0·78).
Discussion
Epidemiological data for the prevalence of hepatitis D virus are needed to inform drug development and guide the formulation of policy on prevention, diagnosis, and management of the infection in sub-Saharan Africa, in agreement with recommendations from WHO. 51 In this systematic review and meta-analysis, the estimated prevalence of anti-hepatitis D virus among general HBsAg-positive populations in sub-Saharan Africa was 8·39% (95% CI 4·73-12·85), which exceeded the estimated global prevalence of 5%. 5 Relating these findings to the prevalence of hepatitis B virus infection would provide an estimated population prevalence of hepatitis B virus and D virus co-infection in sub-Saharan Africa of 0·7%, corresponding to around 7 million people.
Enzyme immunoassay, the method of screening for hepatitis D virus that was used in the included studies, provides case ascertainment of superinfection with hepatitis D virus in carriers of hepatitis B virus, but is thought to be less reliable for the detection of simultaneous hepatitis B virus and D virus co-infection because of high rates of virus clearance and subsequent disappearance of anti-hepatitis D virus. 5, 52 Hepatitis D virus RNA was measured in participants positive for anti-hepatitis D virus in only 16 cohorts, only ten of which tested more than ten participants. In Mauritania, prevalence of RNA detection was consistent across populations, including pregnant women, blood donors, medical outpatients, and attendees at hepatology clinics, at around 62-69%. RNA was detected at a similar frequency in patients with liver disease in central Africa. Available data overall suggest persistent active hepatitis D virus replication in most patients positive for anti-hepatitis D virus, at least in settings with high seroprevalence. In settings with low seroprevalence, RNA was tested for in too few participants to draw firm conclusions about the prevalence of RNA positivity, and the resulting wide CIs overlap with those for estimates of RNA positivity in high-prevalence settings.
Hepatitis D virus seroprevalence was highest among HBsAg-positive populations in central Africa, and lowest in east and southern Africa, although more data are needed from the latter two regions to confirm these findings. Even across similar populations from close geographical regions, seroprevalence was notably heterogeneous. Consistent testing methods (ie, seven commercial assays) were used in all published studies, and thus available data suggest localised clusters of endemicity across sub-Saharan Africa. We did not identify an association between HIV status and hepatitis D virus seroprevalence, although HIV-positive and HIV-negative people in the same population were directly compared in only one study. Furthermore, HIV status was not ascertained in almost half the included studies. Thus, the absence of an association with HIV status should be interpreted with caution, and this finding contrasts with 
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Hepatitis D virus infection is associated with accelerated progression to cirrhosis and increased incidence of hepatocellular carcinoma in carriers of hepatitis B virus, and cross-sectional assessments of hepatitis D virus seroprevalence can therefore be affected by survivorship bias. 5, 52 In European populations, 15% of patients with chronic hepatitis D virus infection progress to cirrhosis within 1-2 years, and 70-80% progress within 5-10 years. 55 Natural history data have not been reported in African populations or for hepatitis D virus genotypes 5-8, which are specific to the continent. Studies in which convenience 
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Lower odds of seropositivity among people with cirrhosis or HCC samp ling of hepatology units was done are helpful to capture the burden of hepatitis D virus among patients with severe liver disease, and our analysis suggests an increased likelihood of seropositivity among HBsAgpositive people with liver disease compared with asymptomatic controls without liver disease in subSaharan Africa. However, data are insufficient to derive an estimation of the burden of liver disease attributable to hepatitis D virus in sub-Saharan Africa, because liver disease was incompletely characterised as a result of the poor availability of validated measures of liver fibrosis. 56 Our analysis has several limitations, which point to important research needs. First, we grouped various 57 RNA testing is not without problems, however. Evidence from an international external quality-control assessment suggested frequent false-negative results among 28 participating laboratories in 17 countries, particularly with the Africaspecific genotypes 5-8; thus, RNA detection might not provide adequate confirmation without rigorous standardisation. 58 Finally, our regional pooled estimates of hepatitis D virus seroprevalence have wide CIs, reflecting the substantial heterogeneity of the available data. 59 We adopted a random-effects model a priori to account for anticipated heterogeneity. 12 In summary, our analysis provides a preliminary estimate of the epidemiology of hepatitis D virus infection in sub-Saharan Africa, and points to several important gaps in knowledge and directions for future research. Results suggest that co-infection with hepatitis B and D viruses could represent an important cause of liver disease in some regions and populations. Improved and systematically collected epidemiology data are needed, particularly for east and southern Africa, as is identification of risk factors for hepatitis D virus transmission. A clinical characterisation of hepatitis D virus infection is needed, particularly for the genotypes 5-8. A focus on patients with established liver disease is required to ascertain the burden of adverse hepatic outcomes attributable to hepatitis D virus. Future research initiatives should be accompanied by an assessment of the reliability of testing methods in the African setting.
Hepatitis B virus infection remains endemic across subSaharan Africa 60 and improved implementation of measures to prevent hepatitis B virus infection-including vaccination, prevention of needle reuse in health care, quality-assured transfusion screening, and expansion of diagnosis and treatment services-is required to reduce the burden of both infections. 50 Mathematical modelling suggests that maintaining infant hepatitis B virus vaccination coverage above 80% and improving birth-dose vaccination coverage for children born to HBsAg-positive mothers (presently less than 10% in sub-Saharan Africa), represents an effective strategy for the eradication of both hepatitis B and D virus infection. 61, 62 Contributors AJS did the literature search, appraised study quality, extracted, analysed, and interpreted data, did laboratory work, and wrote and revised the Article. MC developed the study, assessed studies for inclusion, appraised study quality, and reviewed the Article. AB did phylogenetic analysis of hepatitis D virus sequences and reviewed the Article. ROP developed the study and reviewed the Article. PCM provided input into data interpretation and reviewed the Article. AP and SK did laboratory work. LB provided statistical support. AMG designed the study, interpreted data, and wrote and revised the Article.
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